UB Paderborn / Katalog / Suche / in CDI

P1134 DURATION OF UNDETECTABLE HCVRNA IN PATIENTS TREATED WITH FALDAPREVIR–DELEOBUVIR INTERFERON-FREE COMBINATION IS ASSOCIATED WITH SVR

Journal of hepatology, 2014-04, Vol.60 (1), p.S459-S460

2014

Volltextzugriff (PDF)

P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION

Journal of hepatology, 2014-04, Vol.60 (1), p.S311-S311

2014

Volltextzugriff (PDF)

P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES

Journal of hepatology, 2014-04, Vol.60 (1), p.S310-S311

2014

Volltextzugriff (PDF)

Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

Expert opinion on pharmacotherapy, 2010-08, Vol.11 (11), p.1787-1804

2010

Volltextzugriff (PDF)

Efficacy, safety, and gastrointestinal tolerability of tapentadol ER in a randomized, double-blind, placebo- and active-controlled phase III study of patients with chronic low back pain

The journal of pain, 2009-04, Vol.10 (4), p.S48-S48

2009

Volltextzugriff (PDF)

Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial

Clinical therapeutics, 2015-11, Vol.37 (11), p.2420-2438

2015

Volltextzugriff (PDF)

Efficacy and safety of tapentadol ER for chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study

The journal of pain, 2009-04, Vol.10 (4), p.S50-S50

2009

Volltextzugriff (PDF)

708 RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL OF TAPENTADOL EXTENDED RELEASE FOR CHRONIC LOW BACK PAIN

European journal of pain, 2009-09, Vol.13 (S1), p.S204-S204

2009

Volltextzugriff (PDF)

Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study

Atherosclerosis, 2014-01, Vol.232 (1), p.86-93

2014

Volltextzugriff (PDF)

Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results

Journal of hypertension, 2014-12, Vol.32 (12), p.2488-2498

2014

Volltextzugriff (PDF)

Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial

Journal of human hypertension, 2017-03, Vol.31 (3), p.178-188

2017

Volltextzugriff (PDF)

Osteoarthritis [119-126]: 119. The Value of HFE Genotyping in Exceptional Osteoarthritis

Rheumatology (Oxford, England), 2010-04, Vol.49 (Supplement 1), p.i78-i80

2010

Volltextzugriff (PDF)

Acquired immunodeficiency syndrome and gastrointestinal immune function

Current opinion in gastroenterology, 1992-12, Vol.8 (6), p.1010-1014

1992

Volltextzugriff (PDF)

Crystal Structures of KPC-2 β-Lactamase in Complex with 3-Nitrophenyl Boronic Acid and the Penam Sulfone PSR-3-226

Antimicrobial Agents and Chemotherapy, 2012-05, Vol.56 (5), p.2713-2718

2012

Volltextzugriff (PDF)

Penam sulfones and β-lactamase inhibition: SA2-13 and the importance of the C2 side chain length and composition

PloS one, 2014, Vol.9 (1), p.e85892

2014

Volltextzugriff (PDF)

Structures of SHV-1 β-lactamase with penem and penam sulfone inhibitors that form cyclic intermediates stabilized by carbonyl conjugation

PloS one, 2012-11, Vol.7 (11), p.e49035-e49035

2012

Volltextzugriff (PDF)

LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48

Journal of antimicrobial chemotherapy, 2016-08, Vol.71 (8), p.2171-2180

2016

Volltextzugriff (PDF)

Penicillin Sulfone Inhibitors of Class D β-Lactamases

Antimicrobial Agents and Chemotherapy, 2010-04, Vol.54 (4), p.1414-1424

2010

Volltextzugriff (PDF)

Ligand-Dependent Disorder of the Ω Loop Observed in Extended-Spectrum SHV-Type β-Lactamase

Antimicrobial Agents and Chemotherapy, 2011-05, Vol.55 (5), p.2303-2309

2011

Volltextzugriff (PDF)

Design, Synthesis, and Crystal Structures of 6-Alkylidene-2′-Substituted Penicillanic Acid Sulfones as Potent Inhibitors of Acinetobacter baumannii OXA-24 Carbapenemase

Journal of the American Chemical Society, 2010-09, Vol.132 (38), p.13320-13331

2010

Volltextzugriff (PDF)

β‑Lactamase Inhibition by 7‑Alkylidenecephalosporin Sulfones: Allylic Transposition and Formation of an Unprecedented Stabilized Acyl-Enzyme

Journal of the American Chemical Society, 2013-12, Vol.135 (49), p.18358-18369

2013

Volltextzugriff (PDF)

Carboxylation and Decarboxylation of Active Site Lys 84 Controls the Activity of OXA-24 β-Lactamase of Acinetobacter baumannii: Raman Crystallographic and Solution Evidence

Journal of the American Chemical Society, 2012-07, Vol.134 (27), p.11206-11215

2012

Volltextzugriff (PDF)

Different Intermediate Populations Formed by Tazobactam, Sulbactam, and Clavulanate Reacting with SHV-1 β-Lactamases: Raman Crystallographic Evidence

Journal of the American Chemical Society, 2009-02, Vol.131 (6), p.2338-2347

2009

Volltextzugriff (PDF)

Sulbactam Forms Only Minimal Amounts of Irreversible Acrylate-Enzyme with SHV-1 β-Lactamase

Biochemistry (Easton), 2007-08, Vol.46 (31), p.8980-8987

2007

Volltextzugriff (PDF)

Detecting a Quasi-stable Imine Species on the Reaction Pathway of SHV‑1 β‑Lactamase and 6β-(Hydroxymethyl)penicillanic Acid Sulfone

Biochemistry (Easton), 2015-01, Vol.54 (3), p.734-743

2015

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

P1134 DURATION OF UNDETECTABLE HCVRNA IN PATIENTS TREATED WITH FALDAPREVIR–DELEOBUVIR INTERFERON-FREE COMBINATION IS ASSOCIATED WITH SVR

P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION

P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES

Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

Efficacy, safety, and gastrointestinal tolerability of tapentadol ER in a randomized, double-blind, placebo- and active-controlled phase III study of patients with chronic low back pain

Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial

Efficacy and safety of tapentadol ER for chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study

708 RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL OF TAPENTADOL EXTENDED RELEASE FOR CHRONIC LOW BACK PAIN

Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study

Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results

Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial

Osteoarthritis [119-126]: 119. The Value of HFE Genotyping in Exceptional Osteoarthritis

Acquired immunodeficiency syndrome and gastrointestinal immune function

Crystal Structures of KPC-2 β-Lactamase in Complex with 3-Nitrophenyl Boronic Acid and the Penam Sulfone PSR-3-226

Penam sulfones and β-lactamase inhibition: SA2-13 and the importance of the C2 side chain length and composition

Structures of SHV-1 β-lactamase with penem and penam sulfone inhibitors that form cyclic intermediates stabilized by carbonyl conjugation

LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48

Penicillin Sulfone Inhibitors of Class D β-Lactamases

Ligand-Dependent Disorder of the Ω Loop Observed in Extended-Spectrum SHV-Type β-Lactamase

Design, Synthesis, and Crystal Structures of 6-Alkylidene-2′-Substituted Penicillanic Acid Sulfones as Potent Inhibitors of Acinetobacter baumannii OXA-24 Carbapenemase

β‑Lactamase Inhibition by 7‑Alkylidenecephalosporin Sulfones: Allylic Transposition and Formation of an Unprecedented Stabilized Acyl-Enzyme

Carboxylation and Decarboxylation of Active Site Lys 84 Controls the Activity of OXA-24 β-Lactamase of Acinetobacter baumannii: Raman Crystallographic and Solution Evidence

Different Intermediate Populations Formed by Tazobactam, Sulbactam, and Clavulanate Reacting with SHV-1 β-Lactamases: Raman Crystallographic Evidence

Sulbactam Forms Only Minimal Amounts of Irreversible Acrylate-Enzyme with SHV-1 β-Lactamase

Detecting a Quasi-stable Imine Species on the Reaction Pathway of SHV‑1 β‑Lactamase and 6β-(Hydroxymethyl)penicillanic Acid Sulfone

Suchergebnisse filtern